Pharma Export Milestone at a Glance
- Commercial Milestone: First Sri Lankan drug maker to establish direct overseas field marketing
- Export Destination: Kingdom of Cambodia (Initial commercial shipment dispatched Nov 11, 2026)
- Regulatory Approvals: 13 oral solid dosage formulations registered with Cambodia Health Ministry
- Corporate Parent: Morison PLC operating under Hemas Holdings healthcare cluster
- Manufacturing Center: Produced at state-of-the-art Homagama research and manufacturing complex
COLOMBO (SriLankaBiz): The inaugural Morison pharma export shipment was dispatched to Cambodia in mid-November 2026, establishing Sri Lanka first direct, on-the-ground overseas pharmaceutical marketing and commercial distribution presence.
The consignment, dispatched on November 11 from the company research and manufacturing facility in Homagama, positions Morison PLC as a pioneer domestic drug producer establishing dedicated in-country medical representative teams abroad.
Regulatory Approvals Anchor Morison Pharma Export Shipment
Morison, a sixty-year-old pharmaceutical manufacturer operating within the Hemas Holdings healthcare portfolio, secured thirteen product registrations from the Ministry of Health of Cambodia prior to commercial rollout. Several supplementary therapeutic dossiers remain under active regulatory evaluation.
Unlike traditional third-party merchant trading arrangements where manufacturers sell through passive foreign distributors, Morison appointed a Sri Lankan country manager and deployed a localized medical representative cadre in Phnom Penh. The dedicated sales force will directly detail brand formulations to medical practitioners, private hospitals, and retail pharmacy networks across Cambodian provinces.
| Operational Element | Project Specification | Regulatory Agency | Commercial Scope |
|---|---|---|---|
| Initial Export Dispatch | Dispatched November 11, 2026 | National Medicines Regulatory Authority | First direct overseas marketing launch |
| Registered Formulations | 13 Approved Product Dossiers | Ministry of Health of Cambodia | Oral solid dosage cardiovascular and antibiotics |
| Overseas Management | Expatriate Country Head | Cambodian Commercial Registry | In-house medical representative teams |
| Production Facility | Homagama Research Complex | EU-GMP Compliant Standards | Annual capacity of 5 billion tablets |
Manufacturing Scale and Export Diversification
The launch of the Morison pharma export shipment reflects the company strategy to commercialize excess production capacity at its cutting-edge manufacturing facility in Homagama. Built with an investment exceeding forty million dollars, the facility has an annual production capacity of five billion tablets and two billion capsules.
While the domestic state procurement system absorbed substantial volumes during the foreign currency shortages of recent years, sustained revenue growth requires expanding into higher-margin regional private markets. Cambodia private pharmaceutical market, growing at approximately eight percent annually, presents favorable demographics with minimal local manufacturing competition.
Strategic Impact for Sri Lankan Healthcare Manufacturers
The successful dispatch of the Morison pharma export shipment establishes an operational blueprint for Sri Lanka broader export manufacturing sector. Historically dominated by apparel, tea, and rubber products, Sri Lanka export profile benefits significantly from high-technology knowledge-based manufacturing.
By establishing direct commercial infrastructure overseas, Morison captures distributor margins that traditionally leak to regional intermediaries. For parent group Hemas Holdings, opening Southeast Asian export corridors diversifies group foreign currency inflows, shielding earnings from domestic fiscal adjustments while enhancing brand equity across emerging healthcare markets.


